Normal tissue radiobiology: from the laboratory to the clinic.
This manuscript is in four parts, presenting the four talks given in a symposium on normal tissue radiobiology. The first part addresses the general concept of the role of parenchymal cell radiosensitivity vs. other factors, highlighting research over the last decade that has altered our understanding of factors underlying normal tissue response. The other three parts expand on specific themes raised in the first part dealing in particular with (1) modifications of fibroblast response to irradiation in relation to the induction of tissue fibrosis, (2) the use of the linear-quadratic equation to model the potential benefits of using different means (both physical and biologic) of modifying normal tissue response, and (3) the specific role of the growth factor TFG-beta1 in normal tissue response to irradiation. The symposium highlights the complexities of the radiobiology of late normal tissue responses, yet provides evidence and ideas about how the clinical problem of such responses may be modified or alleviated.
Hill
R P
RP
Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada. hill@oci.utoronto.ca
Rodemann
H P
HP
Hendry
J H
JH
Roberts
S A
SA
Anscher
M S
MS
D000818:Animals; D001260:Ataxia Telangiectasia / Q000532:radiotherapy; D002454:Cell Differentiation; D002470:Cell Survival; D016207:Cytokines / Q000378:metabolism; D004059:Diffusion of Innovation; D019583:Dose Fractionation, Radiation; D004307:Dose-Response Relationship, Radiation; D005347:Fibroblasts / Q000502:physiology / Q000528:radiation effects; D005355:Fibrosis / Q000209:etiology; D006801:Humans; D016014:Linear Models; D008168:Lung / Q000378:metabolism / Q000528:radiation effects; D051379:Mice; D016513:Mice, SCID; D008954:Models, Biological; D009928:Organ Specificity; D011832:Radiation Injuries / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D011836:Radiation Tolerance / Q000502:physiology*; D011853:Radiobiology; D051381:Rats; D012062:Relative Biological Effectiveness; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000502:physiology*; D053773:Transforming Growth Factor beta1; D016896:Treatment Outcome; D015854:Up-Regulation
D016207:Cytokines; C508960:TGFB1 protein, human; C508961:Tgfb1 protein, mouse; C508962:Tgfb1 protein, rat; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1